PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2111511
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2111511
OrthobiologicsMarket size was valued at US$ 7,180.3 Million in 2025, expanding at a CAGR of 10.9% from 2026 to 2033.
Orthobiologics are natural therapies that involve the use of biological materials from the body in treating various musculoskeletal diseases. Orthobiologics have been employed in the treatment of bones, cartilages, tendons, and ligaments in orthopedic treatments in order to enhance their capability of regeneration and repair. Orthobiologics seek to promote the process of accelerated recovery and improvement in surgical operations such as spinal fusion, fractures, and reconstruction.
There are various kinds of orthobiologic materials, which include viscosupplements, bone growth factors, demineralized bone matrix, synthetic bone grafts, and cellular allografts, among others. Viscosupplements are gel preparations that are injected into the joints in order to relieve joint pains and improve their flexibility; this helps in the treatment of arthritis. The injections can be applied in various fields, including spine fusion, maxillofacial and dental, and soft tissue augmentation and reconstruction. In conclusion, orthobiologics play an important role in regeneration and pain relief in surgical treatments.
Orthobiologics Market- Market Dynamics
Increasing Road Accidents and Sports Injuries to Boost Market Demand
Increasing road accidents and sports injuries are the key factors that drive growth in the market for orthobiologics because of the usage of innovative products for repairing the bones and tissues. Application of orthobiologics has helped in speeding up the recovery process and providing better results in the case of treating fractures, joint injuries, and sports injuries and improving mobility and functionality. For instance, in June 2026, according to the Australian Institute of Health and Welfare (Gov), around 19.2 million Australians aged 15 years and above (85%) had participated in sports activities and physical activity, out of which 12% of participants, or 7200 cases, had sustained sports injuries while riding bicycles. Where football accounts for 18% of sports injuries (10,900 cases), the risk factor is high, thus spurring the Orthobiologics market in order to resolve these issues. Thus, there is a high risk of injuries, thereby fueling the demand for orthobiologic solutions.
The Global Orthobiologics market is segmented on the basis of Product Type, Application, End User, and Region.
Demineralized Bone Matrix (DBM) products hold a significant share in the orthobiologics market. This is mainly due to the fact that the DBM products are widely used in bone grafting and orthopedic surgery because of their osteoconductive and osteoinductive characteristics and thus help in the process of regeneration and healing of the bone. For example, in October 2025, according to the study conducted by ACS (Org.), three-dimensional microporous DBM with BMSCs was tested in a bone defect model using micro-CT and histology analysis. There was a rise in the bone formation rates at 4 weeks and 8 weeks post-operation. The porous and cross-linked DBM had more surface for adhesion and proliferation of BMSCs and released osteoinductive factors such as TGF-B, FGFs, BMPs, and IGFs. Thus, DBM products helped in bone growth in vitro by facilitating cell attachments and growth of osteogenic cells.
Orthobiologics Market- Geographical Insights
North America held a notable position in the angiographic catheter market due to the existence of technology development and well-developed healthcare infrastructure. In addition, the region is supported by favorable reimbursement policies and regulatory frameworks that promote the growth of the market. For example, according to the U.S. Medicare Payment Advisory Commission (Gov), in 2026, the payment rates for physician and other health professional services were proposed to increase in 2027 by 0.5 percentage points above the rate set by the current law in 2026. This resulted in an overall increase in the payment rate for physicians and other health professionals practicing in A-APMs to 1.25% and others to 0.75%. These favorable reimbursement policies are expected to further strengthen market growth across North America.
The Orthobiologics market includes key players such as Medtronic plc, Stryker Corporation, Zimmer Biomet Holdings, Inc., DePuy Synthes (Johnson & Johnson), and Smith+Nephew plc. These firms are working on product innovations in order to increase their market share and adapt to the changing demands of orthopedic procedures. In May 2026, DePuy Synthes signed an exclusive distribution deal with CGBIO for NOVOSIS, which is used as a bone graft substitute for the treatment of spine, craniomaxillofacial, and trauma disorders. Such developments are expected to bring innovations in the orthobiologics market.
In March 2026, Vericel Corporation got FDA approval for the manufacture of MACI(R) in its new advanced therapy manufacturing facility, which greatly raised the production capacity of its cartilage restoration treatment.
In January 2025, LifeNet Health introduced PliaFX(R) Flo, a new-generation demineralized bone matrix with fiber that is available in a prefilled syringe for better handling and applications in spinal surgery and orthopedic treatments.